A share price of Ironwood Pharmaceuticals Inc [IRWD] is currently trading at $1.54, up 4.05%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling.
From an analyst’s perspective:
Ironwood Pharmaceuticals Inc [NASDAQ: IRWD] stock has seen the most recent analyst activity on September 09, 2024, when Leerink Partners initiated its Market Perform rating and assigned the stock a price target of $5. Previously, CapitalOne downgraded its rating to Equal Weight on August 08, 2024, and dropped its price target to $4. On January 17, 2024, Craig Hallum initiated with a Buy rating and assigned a price target of $21 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $20 on December 14, 2023. Jefferies initiated its recommendation with a Buy and recommended $21 as its price target on November 09, 2023. JMP Securities started tracking with a Mkt Outperform rating for this stock on September 28, 2023, and assigned it a price target of $22. In a note dated September 02, 2022, CapitalOne initiated an Overweight rating and provided a target price of $15 on this stock.
Ironwood Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $1.34 and $9.23. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Ironwood Pharmaceuticals Inc [NASDAQ: IRWD] shares were valued at $1.54 at the most recent close of the market. An investor can expect a potential return of 354.55% based on the average IRWD price forecast.
Analyzing the IRWD fundamentals
Trailing Twelve Months sales for Ironwood Pharmaceuticals Inc [NASDAQ:IRWD] were 351.41M which represents -22.98% decline. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at 0.28%, Pretax Profit Margin comes in at 0.19%, and Net Profit Margin reading is 0.21%. To continue investigating profitability, this company’s Return on Assets is posted at 0.19, Equity is -0.22 and Total Capital is 0.29. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.97.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.4333 points at the first support level, and at 1.3267 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.5933, and for the 2nd resistance point, it is at 1.6467.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Ironwood Pharmaceuticals Inc [NASDAQ:IRWD] is 4.66. Further, the Quick Ratio stands at 3.62, while the Cash Ratio is 1.79. Considering the valuation of this stock, the price to sales ratio is 0.70 and price to earnings (TTM) ratio is 142.59.
Transactions by insiders
Recent insider trading involved MCCOURT Thomas A, Chief Executive Officer, that happened on Feb 10 ’25 when 0.14 million shares were sold. Principal Accounting Officer, Silver Ronald completed a deal on Feb 10 ’25 to sell 12048.0 shares. Meanwhile, SVP, CMO, Head-Res&Drug Shetzline Michael sold 41269.0 shares on Feb 10 ’25.
